Bioequivalence of Oral Products and the Biopharmaceutics Classification System: Science, Regulation, and Public Policy

被引：36

作者：

Amidon, K. S. ^{[2
]}

Langguth, P. ^{[3
]}

Lennernas, H. ^{[4
]}

Yu, L. ^{[5
]}

Amidon, G. L. ^{[1
]}

机构：

[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA

[2] Iowa State Univ, Dept World Languages & Cultures, Ames, IA USA

[3] Johannes Gutenberg Univ Mainz, Dept Biopharm & Pharmaceut Technol, Mainz, Germany

[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden

[5] US FDA, Off Gener Drugs, Rockville, MD 20857 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 03期

关键词：

INTESTINAL PERMEABILITY; UNITED-STATES; DRUG; CACO-2; BCS; FDA;

D O I：

10.1038/clpt.2011.109

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a product that performs as indicated by the label. The BE standard for a particular product is set by its innovator, and this standard must subsequently be matched by generic drug products. The Biopharmaceutics Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to BE as a pharmaceutical product standard.

引用

页码：467 / 470

页数：4

共 50 条

[31] Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir
Vaithianathan, Soundarya
Haidar, Sam H.
Zhang, Xinyuan
Jiang, Wenlei
Avon, Christopher
Dowling, Thomas C.
Shao, Changxing
Kane, Maureen
Hoag, Stephen W.
Flasar, Mark H.
Ting, Tricia Y.
Polli, James E.
JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (02) : 996 - 1005
[32] Silk fibroin nanoparticles as a versatile oral delivery system for drugs of different biopharmaceutics classification system (BCS) classes: A comprehensive comparison
Duy Toan Pham
Thi Kim Quy Ha
Manh Quan Nguyen
Van De Tran
Viet Bach Nguyen
Tran Thi Bich Quyen
Journal of Materials Research, 2022, 37 : 4169 - 4181
[33] Development of Sentiment Classification System for Indonesian Public Policy Tweet
Setyanugraha, David
Purwarianti, Ayu
2015 INTERNATIONAL CONFERENCE ON COMPUTER, CONTROL, INFORMATICS AND ITS APPLICATIONS (IC3INA), 2015, : 1 - 5
[34] Electronic cigarettes: an update on products, regulation, public health approaches and oral health
Weke, Anthony
Holliday, Richard
COMMUNITY DENTAL HEALTH, 2022, 39 (02) : 68 - 73
[35] Evolution of the Biopharmaceutics Classification System (BCS) to oral Modified Release (MR) formulations; what do we need to consider?
Wilding, IR
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (03) : 157 - 159
[36] Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations; what do we need to consider?
Eur J Pharm Sci, 3 (157-159):
[37] Carcinogens in consumer products: How science can inform policy to benefit public health
Singla, Veena
Woodruff, Tracey
CANCER PREVENTION RESEARCH, 2020, 13 (07) : 23 - 24
[38] Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
Somani, Amit A.
Thelen, Kirstin
Zheng, Songmao
Trame, Mirjam N.
Coboeken, Katrin
Meyer, Michaela
Schnizler, Katrin
Ince, Ibrahim
Willmann, Stefan
Schmidt, Stephan
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (01) : 137 - 147
[39] Developing Integrated Classification System to Provide Systematic Information of Science and Technology Policy
Hong, Seulki
PROCEEDINGS OF 2017 2ND INTERNATIONAL CONFERENCE ON KNOWLEDGE ENGINEERING AND APPLICATIONS (ICKEA), 2017, : 81 - 86
[40] Bioequivalence of Oral Drug Products in the Healthy and Special Populations: Assessment and Prediction Using a Newly Developed In Vitro System "BE Checker"
Masada, Takato
Takagi, Toshihide
Minami, Keiko
Kataoka, Makoto
Izutsu, Ken-ichi
Matsui, Kazuki
Yamashita, Shinji
PHARMACEUTICS, 2021, 13 (08)

← 1 2 3 4 5 →